SCHEMBL15898

SCHEMBL15898

[CH]1OC=CCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331159 0.73
SCHEMBL2640146 0.65
SCHEMBL2554291 0.64
SCHEMBL1434293 0.62
SCHEMBL1552111 0.58 TSHR (0.41)
SCHEMBL11025 0.55
SCHEMBL1956229 0.55
SCHEMBL13113895 0.55
SCHEMBL460530 0.55
SCHEMBL51249 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1030 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109265471-B FXR receptor agonists 轩竹生物科技有限公司 2021-06-04 CN claimed
US-10370403-B2 Methods for the synthesis of ceragenins BRIGHAM YOUNG UNIVERSITY (US) 2019-08-06 US claimed
US-20180243298-A1 TRPV3 MODULATORS ABBVIE INC. 2018-08-30 US claimed
US-RE47009-E1 HDAC inhibitors and therapeutic methods using the same THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2018-08-28 US claimed
WO-2016160938-A1 N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS ABBVIE INC. (US) 2016-10-06 WO claimed
US-9249087-B2 HDAC inhibitors and therapeutic methods using the same THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-02-02 US claimed
US-8961959-B2 Glucosylceramide synthase inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-02-24 US claimed
US-20140128408-A1 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-08 US claimed
EP-2670733-A2 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Board of Trustees of the University of Illinois (US) 2013-12-11 EP claimed
US-20130095089-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-04-18 US claimed
WO-2012106343-A2 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-08-09 WO claimed
US-6960587-B2 Condensed pyrazindione derivatives as PDE inhibitors LILLY ICOS LLC (US) 2005-11-01 US claimed
EP-1366050-B1 CONDENSED PYRAZINDIONE DERIVATIVES AS PDE INHIBITORS LILLY ICOS LLC (US) 2005-04-13 EP claimed
US-20040038978-A1 Chemical compounds LILLY ICOS LLC, A DELAWARE CORPORATION 2004-02-26 US claimed
EP-1366050-A2 CONDENSED PYRAZINDIONE DERIVATIVES AS PDE INHIBITORS Lilly Icos LLC (US) 2003-12-03 EP claimed
WO-2002038563-A2 CONDENSED PYRAZINDIONE DERIVATIVES AS PDE INHIBITORS LILLY ICOS LLC (US) 2002-05-16 WO claimed
US-12043637-B2 Fluorescent dyes containing bis-boron fused heterocycles and uses in sequencing ILLUMINA CAMBRIDGE LIMITED (GB) 2024-07-23 US disclosed
US-20240239843-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS VIKING THERAPEUTICS, INC. 2024-07-18 US disclosed
WO-1995035283-A1 TRI-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS CELLTECH THERAPEUTICS LIMITED (GB) 1995-12-28 WO disclosed
EP-0537463-A2 Substituted pyrido(2,3-d)pyrimidines as antidotes BASF Aktiengesellschaft (DE) 1993-04-21 EP disclosed